( ABBV ), which currently seems to be trading at a discount, could be ideal buy and hold options. ( MRK ), Roche Holding AG ( RHHBY ), and AbbVie Inc. However, we think financially robust mega-cap stocks, Merck & Co., Inc. The market turbulence has led several pharma stocks to slump significantly in price this year. The global pharmaceuticals market is expected to reach $2.14 trillion in 2026 growing at a CAGR of 7.7%, while health spending is expected to balloon from $4 trillion in 2020 to $8.30 trillion by 2040. adults suffering from a chronic disease, this industry is expected to keep growing as the population swells. digital therapeutics companies have increased by approximately 40% a year over the past seven years. According to McKinsey, investments in U.S. Healthcare players are constantly expanding digital health, and this sector has become a hotbed for investors. The solid pace of technological developments in the healthcare industry has fuelled digital healthcare practices, cybersecurity, patient data transparency, remote patient monitoring (RPM), and various customer-centric and operational enhancements. (ABBV), which looks undervalued at their current price levels. (MRK), Roche Holding AG (RHHBY), and AbbVie Inc. So, we think it should be wise to buy and hold mega-cap pharmaceutical stocks Merck & Co. This sector has been attracting massive investments and could remain in the limelight in the near term. Although the heightened market volatility has caused several pharma stocks to slump in price, the sector's long-term prospects look bright.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |